Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Anna Guarini, Maura Brugiatelli et al.|American Journal of Hematology|2014Cited by 114
Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical FeaturesFortunato Morabito, Antonino Neri, Laura Mosca et al.|Clinical Cancer Research|2013Cited by 68
High‐throughput sequencing for the identification of <i><scp>NOTCH</scp>1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implicationsMarta Lionetti, Antonino Neri, Sonia Fabris et al.|British Journal of Haematology|2014Cited by 57
Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic LeukemiaFrancesco Maura, Antonino Neri, Giovanna Cutrona et al.|PLoS ONE|2011Cited by 38
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM studyAntonio Cuneo, Paolo Ghia, George Follows et al.|Haematologica|2018Cited by 35